

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 47

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in *Cumulative List No. 10, 2002* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 47

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la *Liste récapitulative No. 10, 2002* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 47

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran reunidas en *Cumulative List No. 10, 2002* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN *Chemical name or description; Molecular formula; Graphic formula*

DCI Recommandée *Nom chimique ou description; Formule brute; Formule développée*

DCI Recomendada *Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

acidum gadocoleticum

gadocoletic acid


trihydrogen [3β-[[[(4S)-4-[bis[2-[bis[(carboxy-κO)methyl]amino-κM]ethyl]amino-κN]-4-(carboxy-κO)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]]=gadolate(3-)

acide gadocolétique

trihydrogène[3β-[[[(4S)-4-[bis[2-[bis[(carboxy-κO)méthyl]amino-κM]éthyl]amino-κN]-4-(carboxy-κO)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]]=gadolate(3-)

ácido gadocolético

trihidrógeno[3β-[[[(4S)-4-[bis[2-[bis[(carboxi-κO)metil]amino-κM]etil]amino-κN]-4-(carboxi-κO)butanoil]amino]-12α-hidroxi-5β-colan-24-ato(6-)]]=gadolinato(3-)



afele tecanum

afele tecan



camptothecin, ester with *N*-[[*p*-[(3-*O*-methyl-β-*L*-fucopyranosyl)oxy]phenyl]=thiocarbamoyl]-*L*-histidyl-*L*-valine

afélétécán

(2*S*)-2-[[[(2*S*)-3-(1*H*-imidazol-4-yl)-2-[[[4-[(3-*O*-méthyl-6-désoxy-β-*L*-galactopyranosyl)oxy]phényl]amino]thiocarbonyl]amino]propanoyl]amino]-3-méthylbutanoate de (4*S*)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yle

afele tecán

éster de la camptotecina con *N*-[[*p*-[(3-*O*-metil-β-*L*-fucopiranosil)oxi]fenil]=tiocarbamoil]-*L*-histidil-*L*-valina

**alfimeprasum**

alfimeprase


[3-L-serine]fibrolase-(3-203)-peptide (fibrolase : fibrinolytic enzyme isolated from *Agkistrodon conrix conrix* venom)

alfiméprase

[3-L-sérine]fibrolase-(3-203)-peptide (fibrolase : enzyme fibrinolytique extraite de venin d'*Agkistrodon conrix conrix*)

alfimeprasa

[3-L-serina]fibrolasa-(3-203)-péptido (fibrolasa : enzime fibrinolítica extraída de veneno de *Agkistrodon conrix conrix*)



SFPQRYVQ	LVIVADHRMN	TKYNGDSDKI	RQWVHQIVNT
INEIYRPLNI	QFTLVGLEIW	SNQDLITVTS	VSHDTLASFG
NWRETDLLRR	QRHDNAQLLT	AIDFDGDTV	LAYVGGMCQL
KHSTGVIQDH	SAINLLVALT	MAHELGHNLG	MNHDGNQCHC
GANSCVMAAM	LSDQPSKLFS	DCSKKDYQTF	LTVNNPQCIL
NKP			

alicaforsenum

alicaforsen

2'-deoxy-(*R*)-*P*-thioguananylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioadenylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioadenylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioguananylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioguananylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioadenylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioguananylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxyadenosine nonadecasodium salt

alicaforsen

2'-désoxy-(*R*)-*P*-thioguananylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioadénylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioadénylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioguananylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioguananylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioadénylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioguananylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxyadénosine nonadécasodique

alicaforseno

2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioadenilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioadenilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-(*R*)-*P*-tiotimidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioadenilil-(3'→5')-(*R*)-*P*-tiotimidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-(*R*)-*P*-tiotimidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxiadenosina nonadecasódica

**alilusemum**

alilusem


7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4(1*H*)-one
(*E*)-*O*-sulfooxime

alilusem

(*E*)-*O*-sulfooxime de 7-chloro-1-(2-méthylbenzoyl)-2,3-dihydroquinoléin-4(1*H*)-one

alilusem

(*E*)-*O*-sulfooxima de 7-cloro-1-(2-metilbenzoil)-2,3-dihidroquinolin-4(1*H*)-ona





ambrisentanum

ambrisentan (+)-(2*S*)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid

ambrisentan (+)-acide (2*S*)-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3-méthoxy-3,3-diphénylpropanoïque


ambrisentan (+)-ácido (2*S*)-2-[(4,6-dimetilpirimidin-2-il)oxi]-3-metoxi-3,3-difenilpropanoico

**amdoxovirum**

amdoxovir [(2*R*,4*R*)-4-(2,6-diamino-9*H*-purin-9-yl)-1,3-dioxolan-2-yl]methanol

amdoxovir [(2*R*,4*R*)-4-(2,6-diamino-9*H*-purin-9-yl)-1,3-dioxolan-2-yl]méthanol



amdoxovir [(2*R*,4*R*)-4-(2,6-diamino-9*H*-purin-9-il)-1,3-dioxolan-2-il]metanol

**amelubantum**

amelubant ethyl [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]benzyl]oxy]phenyl](imino)methyl]carbamate

amélubant [[4-[[3-[[4-[1-(4-hydroxyphényl)-1-méthyléthyl]phénoxy]méthyl]benzyl]oxy]=phényl](imino)méthyl]carbamate d'éthyle

amelubant [[4-[[3-[[4-[1-(4-hidroxfenil)-1-metiletil]fenoxi]metil]bencil]oxi]fenil](imino)metil]=carbamato de etilo

**amotosalenum**


amotosalen

3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7*H*-furo[3,2-*g*][1]benzopyran-7-one

amotosalène

3-[(2-aminoéthoxy)méthyl]-2,5,9-triméthyl-7*H*-furo[3,2-*g*][1]benzopyran-7-one

amotosaleno

3-[(2-aminoetoxi)metil]-2,5,9-trimetil-7*H*-furo[3,2-*g*][1]benzopiran-7-ona**bimatoprostum**


bimatoprost

(Z)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihydroxy-2-[(1*E*,3*S*)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-*N*-ethyl-5-heptenamide

bimatoprost

(Z)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihydroxy-2-[(1*E*,3*S*)-3-hydroxy-5-phénylpent-1-ényl]cyclopentyl]-*N*-éthylhept-5-énamide

bimatoprost

(Z)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihidroxi-2-[(1*E*,3*S*)-3-hidroxi-5-fenilpent-1-enil]ciclopentil]-*N*-etilhept-5-enamida

caldaretum

caldaret



5-methyl-2-(piperazin-1-yl)benzenesulfonic acid

caldaret

acide 5-méthyl-2-(pipérazin-1-yl)benzènesulfonique

caldaret

ácido 5-metil-2-(piperazin-1-il)benzenosulfónico

**cipralisantum**


cipralisant

4-[(1*R*,2*R*)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1*H*-imidazole

cipralisant

4-[(1*R*,2*R*)-2-(5,5-diméthylhex-1-ynyl)cyclopropyl]-1*H*-imidazole

cipralisant

4-[(1*R*,2*R*)-2-(5,5-dimetilhex-1-inil)ciclopropil]-1*H*-imidazol**darbepoetinum alfa**

darbepoetin alfa


[30-L-asparagine,32-L-threonine,87-L-valine,88-L-asparagine,90-L-threonine]erythropoietin (human)

darbépoétine alfa

[30-L-asparagine,32-L-thréonine,87-L-valine,88-L-asparagine,90-L-thréonine]érythropoïétine humaine

darbepoetina alfa

[30-L-asparagina,32-L-treonina,87-L-valina,88-L-asparagina,90-L-treonina]eritropoietina humana




APPRLICDSR	VLERYLLEAK	EAENITTGCN	ETCSLNENIT
VPDTKVNFYA	WKRMEVGQQA	VEVWQGLALL	SEAVLRGQAL
LVNSSQVNET	LQLHVDKAVS	GLRSLTTLLR	ALGAQKEAIS
PPDAASAAPL	RTITADTFRK	LFRVYSNFLR	GKCLKLYTGEA
CRTGD			

drotrecoginum alfa (activatum)



drotrecogin alfa (activated) blood coagulation factor XIV (human)


drotécogine alfa (activé) facteur XIV humain de coagulation sanguine

drotrecogina alfa (activada) factor XIV de coagulación sanguínea (humano)



* glycosylation sites
 * sites de glycosylation
 * posiciones de glicosilación

**ecalcedenum**ecalcedene 1-[(5Z,7E,20S)-1 α ,3 β -dihydroxy-9,10-secochola-5,7,10(19)-trien-24-oyl]piperidineécalcidène 1-[(5Z,7E,20S)-1 α ,3 β -dihydroxy-9,10-sécochola-5,7,10(19)-trién-24-oyl]pipéridineecalcedeno 1-[(5Z,7E,20S)-1 α ,3 β -dihidroxi-9,10-secocola-5,7,10(19)-trien-24-oil]piperidina

**efalizumabum**

efalizumab

immunoglobulin G1, anti-(human antigen CD11a) (human-mouse monoclonal hu1124 γ 1-chain), disulfide with human-mouse monoclonal hu1124 light chain, dimer

éfalizumab

immunoglobuline G1, anti-(antigène CD11a humain) (chaîne γ 1 de l'anticorps monoclonal de souris humanisé hu1124), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris humanisé hu1124

efalizumab

immunoglobulina G1, anti-(antígeno CD11a humano) (cadena γ 1 del anticuerpo monoclonal humanizado de ratón hu1124), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón hu1124

enfuvirtidum

enfuvirtide



acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L- α -glutamyl-L- α -glutamyl-L-seryl-L-glutaminy-L-asparaginy-L-glutaminy-L-glutaminy-L- α -glutamyl-L-lysyl-L-asparaginy-L- α -glutamyl-L-glutaminy-L- α -glutamyl-L-leucyl-L-leucyl-L- α -glutamyl-L-leucyl-L- α -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginy-L-tryptophyl-L-phenylalaninamide

enfuvirtide


acétyl-L-tyrosyl-L-thréonyl-L-séryl-L-leucyl-L-isoleucyl-L-histidyl-L-séryl-L-leucyl-L-isoleucyl-L- α -glutamyl-L- α -glutamyl-L-séryl-L-glutaminy-L-asparaginy-L-glutaminy-L-glutaminy-L- α -glutamyl-L-lysyl-L-asparaginy-L- α -glutamyl-L-glutaminy-L- α -glutamyl-L-leucyl-L-leucyl-L- α -glutamyl-L-leucyl-L- α -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-séryl-L-leucyl-L-tryptophyl-L-asparaginy-L-tryptophyl-L-phénylalaninamide

enfuvirtida

acetil-L-tirosil-L-treonil-L-seril-L-leucil-L-isoleucil-L-histidil-L-seril-L-leucil-L-isoleucil-L- α -glutamyl-L- α -glutamyl-L-seril-L-glutaminil-L-asparaginil-L-glutaminil-L-glutaminil-L- α -glutamyl-L-lisil-L-asparaginil-L- α -glutamyl-L-glutaminil-L- α -glutamyl-L-leucil-L-leucil-L- α -glutamyl-L-leucil-L- α -aspartil-L-lisil-L-triptofil-L-alanil-L-seril-L-leucil-L-triptofil-L-asparaginil-L-triptofil-L-fenilalaninamida




epafipasum	
epafipase	2-acetyl-1-alkyl- <i>sn</i> -glycero-3-phosphocholine deacetylase-(6-400)-peptide (human)
épafipase	désacétylase-(6-400)-peptide (humaine) de la 2-acétyl-1-alkyl- <i>sn</i> -glycéro-3-phosphocholine
epafipasa	1-O-alkil-2-acetil- <i>sn</i> -glicero-3-fosfocolina 6-400-desacetilasa (humana)



AAASFGQTKI	PRGNPYSVG	CTDLMFDHTN	KGTFRLRYYP
SQDNDRLDTL	WIPNKEYFWG	LSKFLGTHWL	MGNILRLLFG
SMTTPANWNS	PLRPGEKYPL	VVFSHGLGAF	RTLISAIGID
LASHGFIVAA	VEHRDRSASA	TTYFKDQSAA	EIGDKSWLYL
RTLKQEEETH	IRNEQVRQRA	KECSQALSLI	LDIDHGKPVK
NALDLKFDME	QLKDSIDREK	IAVIGHSFGG	ATVIQTLSED
QRFRCGIALD	AWMFPLGDEV	YSRIPQPLFF	INSEYFQYPA
NIIKMKKCYS	PDKERKMITI	RGSVHQNFAD	FTFATGKIIG
HMLKLKGDID	SNVAIDLSNK	ASLAFLQKHL	GLHKDFDQWD
CLIEGDDENL	IPGTNINTTN	QHIMLQNSSG	IEKYN

epoetinum delta	
epoetin delta	1-165-erythropoietin (human HMR4396), glycoform δ
époétine delta	1-165-érythropoïétine (humaine HMR4396), glycoforme δ
epoetina delta	1-165-eritropoietina (humana HMR4396), glicoforma δ



APPR	LICDSR	VLERYLLEAK	EAENITTGCA	EHCSLNEIT
VPDT	KVNFYA	WKRMEVGQA	VEVWQGLALL	SEAVLRGQAL
LVN	SSQPWEP	LQLHVDKAVS	GLRSLTTLR	ALGAQKEAIS
PPDA	ASAAPL	RTITADTRK	LFRVYSNFLR	GKCLKYTGEA
CRTGD				

* : glycosylation sites / sites de glycosylation / posiciones de glicosilación

erlotinibum



erlotinib

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

erlotinib

N-(3-éthynylphényl)-6,7-bis(2-méthoxyéthoxy)quinazolin-4-amine

erlotinib

N-(3-etinilfenil)-6,7-bis(2-metoxietoxi)quinazolin-4-amina**febuxostatatum**

febuxostat



2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

fébuxostat

acide 2-[3-cyano-4-(2-méthylpropoxy)phényl]-4-méthylthiazole-5-carboxylique

febuxostat

ácido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metilthiazol-5-carboxílico





felopreptanum

felopreptan (2*S*)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3,3-diphenylpropanoic acid

félopreptan acide (2*S*)-3-[2-(3,4-diméthoxyphényl)éthoxy]-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3,3-diphénylpropanoïque



felopreptán ácido (2*S*)-3-[2-(3,4-dimetoxifenil)etoxi]-2-[(4,6-dimetilpirimidin-2-il)oxi]-3,3-difenilpropanoico

**finafloxacinum**

finafloxacin (-)-8-cyano-1-cyclopropyl-6-fluoro-7-[(4*aS*,7*aS*)-hexahydropyrrolo[3,4-*b*]-1,4-oxazin-6(2*H*)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

finafloxacine (-)-acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4*aS*,7*aS*)-hexahydropyrrolo[3,4-*b*]-1,4-oxazin-6(2*H*)-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

finafloxacino (-)-ácido 8-ciano-1-ciclopropil-6-fluoro-7-[(4*aS*,7*aS*)-hexahidropirrolo[3,4-*b*]-1,4-oxazin-6(2*H*)-il]-4-oxo-1,4-dihidroquinolina-3-carboxílico


**gadolmelitolum**

gadolmelitol hydrogen [2,2',2'',2'''-[1,4,7,10-tetraazacyclododecane-1,4,7,10-triyl]tetrakis-[5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2*S*,3*R*,4*R*,5*R*)-2,3,4,5,6-pentahydroxyhexyl-2,4,6-tribromo]carbamoyle]phenyl]amino]-2-oxoethyl]carbamoyle]phenyl]=carbamoyle]phenyl]amino]-2-oxoethyl]amino]-5-oxopentanoato](4-)]]=gadolate(1-)

gadolmétilol hydrogéno-[2,2',2'',2'''-[1,4,7,10-tétrazacyclododécane-1,4,7,10-triyl]tétrakis[5-[[2-[[4-[[4-[[2-[[[3,5-bis[bis[(2*S*,3*R*,4*R*,5*R*)-2,3,4,5,6-pentahydroxyhexyl-2,4,6-tribromo]carbamoyle]phényl]amino]-2-oxoéthyl]carbamoyle]phényl]=carbamoyle]phényl]amino]-2-oxoéthyl]amino]-5-oxopentanoato](4-)]]=gadolate(1-)

gadomelitol

hidrógeno-[2,2',2'',2''']-[1,4,7,10-tetraazaciclododecano-1,4,7,10-triil]tetrakis=[5-[[2-[[4-[[[2-[[[3,5-bis[bis[(2*S*,3*R*,4*R*,5*R*)-2,3,4,5,6-pentahidroxihexil-2,4,6-tribromo]carbamoil]fenil]amino]-2-oxoetil]carbamoil]fenil]carbamoil]fenil]=amino]-2-oxoetil]amino]-5-oxopentanoato](4-)]gadolinato(1-)



garnocestimum

garnocestim

5-73-macrophage inflammatory protein 2α (human gene gro2)

garnocestim

CXC chimiokine GROβ-(5-73)-peptide (GROβ : protéine inflammatoire humaine sécrétée par les macrophages)

garnocestim

CXC quimiokina GROβ-(5-73)-péptido (GROβ : proteína inflamatoria humana secretada por los macrófagos)



gefitinibum

gefitinib


N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine

géfitinib

N-(3-chloro-4-fluorophényl)-7-méthoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine

gefitinib

N-(3-cloro-4-fluorofenil)-7-metoxi-6-[3-(morfolin-4-il)propoxi]quinazolin-4-amina

**ingliforibum**

ingliforib


5-chloro-*N*-[(1*S*,2*R*)-1-benzyl-3-(*cis*-3,4-dihydroxypyrrolidin-1-yl)-2-hydroxy-3-oxopropyl]-1*H*-indole-2-carboxamide

ingliforib

5-chloro-*N*-[(1*S*,2*R*)-1-benzyl-3-(*cis*-3,4-dihydroxypyrrolidin-1-yl)-2-hydroxy-3-oxopropyl]-1*H*-indole-2-carboxamide

ingliforib

5-cloro-*N*-[(1*S*,2*R*)-1-bencil-3-(*cis*-3,4-dihidroxipirrolidin-1-il)-2-hidroxi-3-oxopropil]-1*H*-indol-2-carboxamida

**ipravacainum**

ipravacaine


(2*RS*)-1-(cyclopropylmethyl)-2',6'-dimethyl-2-piperidinecarboxanilide

ipravacaïne



(2*RS*)-1-(cyclopropylméthyl)-*N*-(2,6-diméthylphényl)pipéridine-2-carboxamide

ipravacaína

(2*RS*)-1-(ciclopropilmetil)-*N*-(2,6-dimetilfenil)piperidina-2-carboxamida



and enantiomer
et énantiomère
y enantiómero

**lapisteridum**

lapisteride



N-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5 α -androst-1-ene-17 β -carboxamide

lapistéride

N-[1-(4-méthoxyphényl)-1-méthyléthyl]-3-oxo-4-aza-5 α -androst-1-ène-17 β -carboxamide

lapisterida

N-[1-(4-metoxifenil)-1-metiletil]-3-oxo-4-aza-5 α -androst-1-eno-17 β -carboxamida

**laquinimodum**

laquinimod



5-chloro-*N*-ethyl-4-hydroxy-1-methyl-2-oxo-*N*-phenyl-1,2-dihydroquinoline-3-carboxamide

laquinimod

5-chloro-*N*-éthyl-4-hydroxy-1-méthyl-2-oxo-*N*-phényl-1,2-dihydroquinoléine-3-carboxamide

laquinimod

5-cloro-*N*-etil-4-hidroxi-1-metil-2-oxo-*N*-fenil-1,2-dihidroquinolina-3-carboxamida

**laronidasum**


laronidase

8-L-histidine- α -L-iduronidase (human)

laronidase

[8-L-histidine]- α -L-iduronidase humaine

laronidasa

8-L-histidina- α -L-iduronidasa (humana)


AEAPHLVHVD	AARALWPLRR	FWRSTGFCPP	LPHSQADQYV
LSWDQQLNLA	YVGAVPHRGI	KQVRTHWLLE	LVTTRGSTGR
GLSY [*] NFTHLD	GYDLLRENQ	LLPGFELMGS	ASGHFTDFED
KQQVFEWKDL	VSSLARRYIG	RYGLAHVSKW	NFETWNEPDH
HDFD [*] NVSMTM	QGFLNYYDAC	SEGLRAASPA	LRLGGPGDSF
HTPPRSPLSW	GLLRHCHDGT	NFFTGEAGVR	LDYISLHRKG
ARSSISILEQ	EKVVAQQIRQ	LFPKFADTPI	YNDEADPLVG
WSLPQPWRAD	VTYAAMVVKV	IAQHQNLLLA	N [*] TTSAFPYAL
LSNDNAFLSY	HPHPFAQRTL	TARFQV [*] NNTR	PPHVQLLRKP
VLTAMGLLAL	LDEEQLWAEV	SQAGTVLDS [*] N	HTVGVLASAH
RPQGPADAWR	AAVLIYASDD	TRAHP [*] NRSVA	VTLRLRGVPP
GPGLVYVTRY	LDNGLCSPDG	EWRLGRPVF	PTAEQFRMR
AAEDPVAAAP	RPLPAGGRLT	LRPALRLPSL	LLVHV [*] CARPE
KPPGQVTRLR	ALPLTQGQLV	LVWSDEHVG	KCLW [*] TYEIQF
SQDGKAYTPV	SRKPSTFNLF	VFSPDTGAVS	GSYRVRALDY
WARPGPFSDP	VPYLEVPVPR	GPPSPGPNP	

* : glycosylation sites / sites de glycosylation / posiciones de glicosilación

↪ : disulfide / disulfure / disulfuro

lirimilastum

lirimilast	2-(2,4-dichlorobenzoyl)-3-ureidobenzofuran-6-yl methanesulfonate
lirimilast	méthanesulfonate de 2-(2,4-dichlorobenzoyl)-3-uréidobenzofuran-6-yle
lirimilast	metanosulfonato de 2-(2,4-diclorobenzoyl)-3-ureidobenzofuran-6-ilo

**livaraparinum calcium**



livaraparin calcium	calcium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 2-O-sulfo- α -L-idopyranosuronic acid structure at the non-reducing end and a 6-O-sulfo-structure at the reducing end of their chain; the mass-average molecular mass ranges between 3000 and 5000 with 75% is less than 8000; the degree of sulfatation is approximately 2 per disaccharidic unit
---------------------	---

livaraparine calcique	sel calcique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'acide nitreux, d'héparine de muqueuse intestinale de porc ; la majorité des composants de la livaraparine calcique possèdent une structure acide 2-O-sulfo- α -L-idopyranosuronique à l'extrémité non réductrice de leur chaîne et une structure 6-O-sulfatée à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative moyenne est de 3000 à 5000, 75% étant inférieur à 8000 ; le degré de sulfatation par unité disaccharide est voisin de 2
-----------------------	--

livaraparina cálcica	sal cálcica de una heparina de baja masa molecular obtenida de heparina de mucosa intestinal de cerdo por despolimerización con ácido nitroso; la mayoría de los componentes de la livaraparina cálcica tienen ácido 2-O-sulfo- α -L-idopiranosurónico en el extremo no reductor de la cadena y una estructura 6-O-sulfatada en el extremo reductor de la cadena; la masa molecular relativa media es de 3000 a 5000, siendo el 75% inferior a 8000; el grado de sulfatación por unidad de disacárido es aproximadamente 2
----------------------	---

manifaxinum

manifaxine	(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol
manifaxine	(2S,3S,5R)-2-(3,5-difluorophényl)-3,5-diméthylmorpholin-2-ol
manifaxina	(2S,3S,5R)-2-(3,5-difluorofenil)-3,5-dimetilmorfolin-2-ol

**miglustatum**


miglustat

(2*R*,3*R*,4*R*,5*S*)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

miglustat

(2*R*,3*R*,4*R*,5*S*)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol

miglustat

(2*R*,3*R*,4*R*,5*S*)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol**miriplatinum**


miriplatin

(SP-4-2)-[(1*R*,2*R*)-cyclohexane-1,2-diamine-*N,N'*]=bis(tetradecanoato-*O*)platinum

miriplatine

(SP-4-2)-[(1*R*,2*R*)-cyclohexane-1,2-diamine-*N,N'*]=bis(tétradécanoato-*O*)platine

miriplatino



(SP-4-2)-[(1*R*,2*R*)-ciclohexano-1,2-diamina-*N,N'*]=bis(tetradecanoato-*O*)platino

mirostopipenum

mirostopipen [23-methionine]human myeloid progenitor inhibitory factor 1-(23-99)-peptide

mirostopipen [23-méthionine]facteur 1 d'inhibition du précurseur myéloïde humain-(23-99)-peptide


mirostopipeno [23-metionina]-(23-99)-péptido del factor 1 de inhibición del progenitor mieloide humano

**mureletecanum**

mureletecan poly[[N-(2-hydroxypropyl)methacrylamide]-co-[camptothecin ester with N-[6-(2-methacrylamidoacetamido)hexanoyl]glycine]-co-[N-[(2-hydroxypropyl)carbamoyl]methyl]methacrylamide]]

murélétécan copolymère de N-[(2RS)-2-hydroxypropyl]-2-méthylpropénamide, de N-[2-[[6-[[[2-[[[(4S)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléin-4-yl]oxy]-2-oxoéthyl]amino]-6-oxohexyl]amino]-2-oxoéthyl]-2-méthylpropénamide et de N-[2-[[[(2RS)-2-hydroxypropyl]amino]-2-oxoéthyl]-2-méthylpropénamide

mureletecán poli[[N-(2-hidroxiopropil)metacrilamida]-co-[éster de camptotecina con N-[6-(2-metacrilamidoacetamido)hexanoil]glicina]-co-[N-[[[(2-hidroxiopropil)carbamoil]metil]metacrilamida]]



nasaruplasum beta

nasaruplase beta


prourokinase (enzyme-activating) human (clone pUK4/pUK18 protein moiety), glycosylated (murine cell line SP2/0)

nasaruplase bêta

prourokinase (activateur d'enzyme) humaine glycosylée dont le gène est cloné dans le vecteur pUK4/pUK18 et exprimée dans la lignée cellulaire murine SP2/0

nasaruplase beta

prourokinasa (activador de enzima) humana glicosilada cuyo gen se clona en el vector pUK4/pUK18 y se expresa en la línea celular murina SP2/0



SNELHQVPSN	CDCLNGGTCV	SNKYFSNIHW	CNCPKKFGGQ
HCEIDKSKTC	YEGNGHFYRG	KASTDTMGRP	CLPWNSATVL
QQTYHAHRSD	ALQLGLGKHN	YCRNPDNRRR	PWCYVQVGLK
PLVQECMVHD	CADGKKPSSP	PEELKFQCQG	KTLRPRFKII
GGEFTTIENQ	PWFAAIYRRH	RGGSVTYVCG	GSLISPCWVI
SATHCFIDYP	KKEDYIVYLG	RSRLNSNTQG	EMKFEVENLI
LHKDYSADTL	AHHNDIALLK	IRSKEGRCAQ	PSRTIQTICL
PSMYNDPQFG	TSCEITGF GK	ENSTDYLYPE	QLKMTVVKLI
SHRECQQPHY	YGSEVTTKML	CAADPQWKTD	SCQGDSSGPL
VCSLQGRMTL	TGIVSWGRC	ALKDKPGVYT	RVSHFLPWIR
SHTKEENGLA	L		

*: glycosylation sites / sites de glycosylation / posiciones de glicosilación

netoglitazonum


netoglitazone

(5*RS*)-5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]thiazolidine-2,4-dione

nétoglitazone

(5*RS*)-5-[[6-[(2-fluorophényl)méthoxy]naphtalén-2-yl]méthyl]thiazolidine-2,4-dione

netoglitazona

(5*RS*)-5-[[6-[(2-fluorofenil)metoxi]naftalen-2-il]metil]tiiazolidina-2,4-dionaand enantiomer
et énantiomère
y enantiómero

ospemifenum

ospemifene



2-[p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]ethanol

ospémifène

(Z)-2-[4-(4-chloro-1,2-diphénylbut-1-ényl)phénoxy]éthanol

ospemifeno

2-[p-[(Z)-4-cloro-1,2-difenil-1-butenil]fenoxi]etanol

**pegfilgrastimum**



pegfilgrastim

N-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with α -methyl- ω -hydroxypoly(oxyethylene)

pegfilgrastim

N-(3-hydroxypropyl)méthionylfacteur de stimulation de colonie humain, 1-éther avec le α -méthyl- ω -hydroxypoly(oxyéthylène)

pegfilgrastim

N-(3-hidroxiopropil)metionilfactor de estimulación de colonias humano, 1-éter con el α -metil- ω -hidroxipoli(oxietileno)**pexelizumabum**

pexelizumab

immunoglobulin, anti-(human complement C5 α -chain) (human-mouse monoclonal 5G1.1-SC single chain)

pexélizumab

immunoglobuline, anti-(chaîne- α du complément C5 humain) (mono chaîne de l'anticorps monoclonal de souris humanisé 5G1.1-SC)

pexelizumab

inmunoglobulina, anti-(cadena- α del complemento C5 humano) (mono cadena del anticuerpo monoclonal humanizado de ratón 5G1.1-SC)

pralnacasanum



pralnacasan

(1*S*,9*S*)-*N*-[(2*R*,3*S*)-2-ethoxy-5-oxotetrahydrofuran-3-yl]-9-[(isoquinolin-1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-*H*-pyridazino[1,2-*a*][1,2]=diazepine-1-carboxamide

pralnacasan

(1*S*,9*S*)-*N*-[(2*R*,3*S*)-2-éthoxy-5-oxotétrahydrofuran-3-yl]-9-[(isoquinoléin-1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-*H*-pyridazino[1,2-*a*]=[1,2]diazépine-1-carboxamide

pralnacasán

(1*S*,9*S*)-*N*-[(2*R*,3*S*)-2-etoxi-5-oxotetrahidrofuran-3-il]-9-[(isoquinolin-1-ilcarbonyl)amino]-6,10-dioxooctahidro-6-*H*-piridazino[1,2-*a*][1,2]diazepina-1-carboxamida**pratosartanum**


pratosartan

2-propyl-3-[[2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl]methyl]-5,6,7,8-tetrahydrocycloheptaimidazol-4(3*H*)-one

pratosartan

2-propyl-3-[[2'-(1*H*-tétrazol-5-yl)biphényl-4-yl]méthyl]-5,6,7,8-tétrahydrocycloheptaimidazol-4(3*H*)-one

pratosartán

2-propil-3-[[2'-(1*H*-tetrazol-5-il)bifenil-4-il]metil]-5,6,7,8-tetrahidrocicloheptaimidazol-4(3*H*)-ona**ragaglitazarum**

ragaglitazar


(-)-(2*S*)-2-ethoxy-3-[4-[2-(10*H*-phenoxazin-10-yl)ethoxy]phenyl]propanoic acid

ragaglitazar

(-)-acide (2*S*)-2-éthoxy-3-[4-[2-(10*H*-phénoxazin-10-yl)éthoxy]phényl]=propanoïque

ragaglitazar

(-)-ácido (2*S*)-2-etoxi-3-[4-[2-(10*H*-fenoxazin-10-il)etoxi]fenil]propanoico

**reslizumabum**

reslizumab

immunoglobulin G4, anti-(human interleukin 5) (human-rat monoclonal SCH 55700 γ 4-chain), disulfide with human-rat monoclonal SCH 55700 light chain, dimer

reslizumab

immunoglobuline G4, anti-(interleukine 5 humaine), (chaîne γ 4 de l'anticorps monoclonal de rat humanisé SCH 55700), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de rat humanisé SCH 55700

reslizumab

immunoglobulina G4, anti-(interleukina 5 humana), (cadena γ 4 del anticuerpo monoclonal humanizado de rata SCH 55700), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de rata SCH 55700

ruboxistaurinum

ruboxistaurin



(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,19H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-*h*][1,4,13]oxadiazacyclohexadecene-18,20-dione

ruboxistaurine

(9S)-9-[(diméthylamino)méthyl]-6,7,10,11-tétrahydro-9H,19H-5,21:12,17-diméthénodibenzo[e,k]pyrrolo[3,4-*h*][1,4,13]oxadiazacyclohexadécène-18,20-dione

ruboxistaurina

(9S)-9-[(dimetilamino)metil]-6,7,10,11-tetrahidro-9H,19H-5,21:12,17-dimetenodibenzo[e,k]pirrolo[3,4-*h*][1,4,13]oxadiazaciclohexadeceno-18,20-diona



semaxanibum


semaxanib

3-[(*Z*)-(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone

sémaxanib

(*Z*)-3-[(3,5-diméthyl-1*H*-pyrrol-2-yl)méthylène]-1,3-dihydro-2*H*-indol-2-one

semazanib

3-[(*Z*)-(3,5-dimetilpirrol-2-il)metileno]-2-indolinona $C_{15}H_{14}N_2O$ **senazodanum**


senazodan

6-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydropyridazin-3(2*H*)-one

sénazodan

6-[4-(pyridin-4-ylamino)phényl]-4,5-dihydropyridazin-3(2*H*)-one

senazodán

6-[4-(piridin-4-ilamino)fenil]-4,5-dihidropiridazin-3(2*H*)-ona $C_{15}H_{14}N_4O$ **silodosinum**


silodosin

(-)-1-(3-hydroxypropyl)-5-[(2*R*)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-dihydro-1*H*-indole-7-carboxamide

silodosine

(-)-1-(3-hydroxypropyl)-5-[(2*R*)-2-[[2-[2-(2,2,2-trifluoroéthoxy)phénoxy]éthyl]amino]propyl]-2,3-dihydro-1*H*-indole-7-carboxamide

silodosina

(-)-1-(3-hidroxiopropil)-5-[(2*R*)-2-[[2-[2-(2,2,2-trifluoroetoxi)fenoxi]etil]amino]propil]-2,3-dihidro-1*H*-indol-7-carboxamida $C_{25}H_{32}F_3N_3O_4$ 

solifenacinum



solifenacin

(3*R*)-1-azabicyclo[2.2.2]oct-3-yl (1*S*)-1-phenyl-3,4-dihydroisoquinoline-2(1*H*)-carboxylate

solifénacine

(1*S*)-1-phényl-3,4-dihydroisoquinoléine-2(1*H*)-carboxylate de (3*R*)-1-azabicyclo[2.2.2]oct-3-yle

solifenacina

(1*S*)-1-fenil-3,4-dihidroisoquinolina-2(1*H*)-carboxilato de (3*R*)-1-azabicyclo[2.2.2]oct-3-ilo**tadalafilum**



tadalafil

(6*R*,12*aR*)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12*a*-hexahydropyrazino[1',2':1,6]pyrido[3,4-*b*]indole-1,4-dione

tadalafil

(6*R*,12*aR*)-6-(1,3-benzodioxol-5-yl)-2-méthyl-2,3,6,7,12,12*a*-hexahydropyrazino[1',2':1,6]pyrido[3,4-*b*]indole-1,4-dione

tadalafilo

(6*R*,12*aR*)-6-(1,3-benzodioxol-5-il)-2-metil-2,3,6,7,12,12*a*-hexahidropirazino[1',2':1,6]pirido[3,4-*b*]indol-1,4-diona**tafluposidum**

tafluposide


4-[(5*R*,5*aR*,8*aR*,9*S*)-9-[[4,6-*O*-[(1*R*)-ethylidene]-2,3-bis-*O*-[(pentafluorophenoxy)acetyl]-β-*D*-glucopyranosyl]oxy]-6-oxo-5,5*a*,6,8,8*a*,9-hexahydrofuro[3',4':6,7]naphtho[2,3-*d*]-1,3-dioxol-5-yl]-2,6-dimethoxyphenyle dihydrogen phosphate

tafluposide

dihydrogénophosphate de 4-[(5*R*,5*aR*,8*aR*,9*S*)-9-[[4,6-*O*-[(1*R*)-éthylidène]-2,3-bis-*O*-[(pentafluorophénoxy)acétyle]-β-*D*-glucopyranosyl]oxy]-6-oxo-5,5*a*,6,8,8*a*,9-hexahydrofuro[3',4':6,7]naphto[2,3-*d*]-1,3-dioxol-5-yl]-2,6-diméthoxyphényle

taflupósido

dihidrógenofosfato de 4-[(5*R*,5*aR*,8*aR*,9*S*)-9-[[4,6-*O*-[(1*R*)-etilideno]-2,3-bis-*O*-[(pentafluorofenoxi)acetil]-β-*D*-glucopiranosil]oxi]-6-oxo-5,5*a*,6,8,8*a*,9-hexahidrofuro[3',4':6,7]nafto[2,3-*d*]-1,3-dioxol-5-il]-2,6-dimetoxifenilo

**telberminum**

telbermin



vascular endothelial growth factor (human), dimer

telbermine

facteur de croissance de l'endothélium vasculaire humain (dimère)

telbermina

factor de crecimiento del endotelio vascular (humano), dímero



↪ : disulfide / disulfure / disulfuro

tenivastatinum

tenivastatin


(3*R*,5*R*)-7-[(1*S*,2*S*,6*R*,8*S*,8*aR*)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8*a*-hexahydronaphtalen-1-yl]-3,5-dihydroxyheptanoic acid

ténivastatine

acide (3*R*,5*R*)-7-[(1*S*,2*S*,6*R*,8*S*,8*aR*)-8-[(2,2-diméthylbutanoyl)oxy]-2,6-diméthyl-1,2,6,7,8,8*a*-hexahydronaphtalén-1-yl]-3,5-dihydroxyheptanoïque

tenivastatina

ácido (3*R*,5*R*)-7-[(1*S*,2*S*,6*R*,8*S*,8*aR*)-8-[(2,2-dimetilbutanoil)oxi]-2,6-dimetil-1,2,6,7,8,8*a*-hexahidronaftalen-1-il]-3,5-dihidroxiheptanoico

**tesaglitazarum**


tesaglitazar

(2*S*)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]=propanoic acid

tésaglitazar

acide (2*S*)-2-éthoxy-3-[4-[2-[4-[(méthylsulfonyl)oxy]phényl]éthoxy]phényl]=propanoïque

tesaglitazar

ácido (2*S*)-2-etoxi-3-[4-[2-[4-[(metilsulfonil)oxi]fenil]etoxi]fenil]propanoico**tofimilastum**


tofimilast

9-cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine

tofimilast

9-cyclopentyl-7-éthyl-3-(thiophén-2-yl)-6,9-dihydro-5*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine

tofimilast

9-ciclopentil-7-etil-3-(tiofen-2-il)-6,9-dihidro-5*H*-pirazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]piridina

xidecaflurum

xidecaflur


2,2-[(9Z)-9-octadecenylimino]diethanol hydrofluoride

xidécaflur

fluorhydrate de 2,2'-[(9Z)-octadec-9-énylimino]diéthanol

xidecaflur

hidrofluoruro de 2,2 -[(9Z)-9-octadecenilimino]dietanol

**zanapezilum**

zanapezil


3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)propan-1-one

zanapézil

3-(1-benzylpipéridin-4-yl)-1-(2,3,4,5-tétrahydro-1H-1-benzazépin-8-yl)propan-1-one

zanapezilo

3-(1-bencilpiperidin-4-il)-1-(2,3,4,5-tetrahidro-1H-1-benzazepin-8-il)propan-1-ona

**zonampanelum**

zonampanel


[7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid

zonampanel

acide [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acétique

zonampanel

ácido [7-(1H-imidazol-1-il)-6-nitro-2,3-dioxo-3,4-dihidroquinoxalin-1(2H)-il]acético



zoniporidum


zoniporide

N-carbamimidoyl-5-cyclopropyl-1-(quinolin-5-yl)-1*H*-pyrazole-4-carboxamide

zoniporide

N-carbamimidoyl-5-cyclopropyl-1-(quinoléin-5-yl)-1*H*-pyrazole-4-carboxamide

zoniporida

N-carbamimidoil-5-ciclopropil-1-(quinolin-5-il)-1*H*-pyrazol-4-carboxamida $C_{17}H_{16}N_6O$ **zoticasonum**


zoticasone

S-[(3*R*)-2-oxotetrahydrofuran-3-yl] 6 α ,9-difluoro-12 β ,17-dihydroxy-16 α -methyl-3-oxoandrost-1,4-diene-17 β -carbothioate

zoticasone

6 α ,9-difluoro-12 β ,17-dihydroxy-16 α -méthyl-3-oxoandrost-1,4-diène-17 β -carbothioate de *S*-[(3*R*)-2-oxotétrahydrofuran-3-yle]

zoticasona

6 α ,9-difluoro-12 β ,17-dihidroxi-16 α -metil-3-oxoandrost-1,4-dieno-17 β -carbotoiato de *S*-[(3*R*)-2-oxotetrahidrofuran-3-ilo] $C_{25}H_{30}F_2O_5S$ 

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Proposed International Nonproprietary Names (Prop. INN): List 59

Dénominations communes internationales proposées (DCI Prop.): Liste 59

Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 59

(WHO Drug Information/Informations pharmaceutiques OMS/Informaciones farmaceuticas de la OMS, Vol. 2, No. 2, 1988)

p. 16 *delete/supprimer/suprimase* *insert/insérer/insértese*

levoglutamidum

levoglutamide

lévoglutamide

levoglutamida

glutaminum

glutamine

glutamine

glutamina

Recommended International Nonproprietary Names (Rec. INN): List 42

Dénominations communes internationales recommandées (DCI Rec.): Liste 42

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 42

(WHO Drug Information, Vol. 13, No. 3, 1999)

suprimase

insértese

p. 184 carabersato

carabersat

p. 207 tonabersato

tonabersat

Recommended International Nonproprietary Names (Rec. INN): List 44

Dénominations communes internationales recommandées (DCI Rec.): Liste 44

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44

(WHO Drug Information, Vol. 14, No. 3, 2000)

p. 199 *delete/supprimer/suprimase* *insert/insérer/insértese*

nebostinelum

nebostinel

nébostinel

nebostinel

neboglaminum

neboglamine

néboglamine

neboglamina

p. 199 **onerceptum**

onercept

replace the description by the following:

TNF-BP-(20-180)-peptide (part of extracellular domain of the glycosylated human Tumor Necrosis Factor Receptor 1)

onercept

sustitúyase la descripción por la siguiente:

péptido (20-180) TNF-BP (parte del dominio extracelular del receptor 1 humano del factor de necrosis tumoral glicosilado)

Recommended International Nonproprietary Names (Rec. INN): List 45**Dénominations communes internationales recommandées (DCI Rec.): Liste 45****Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 45****(WHO Drug Information, Vol. 15, No. 1, 2001)**p. 55 **evernimicinum**

evernimicina

sustitúyase la descripción por la siguiente:

O-3-C-metil-4-O-metil-3-nitro-2,3,6-tridesoxi- α -L-arabino-hexopiranosil-(1 $\rightarrow$ 3)-O-4-O-(3,5-dicloro-4-hidroxi-2-metoxi-6-metilbenzoil)-2,6-didesoxi- β -D-arabino-hexopiranosil-(1 $\rightarrow$ 4)-O-(1R)-2,6-didesoxi-D-arabino-hexopiranosilideno-(1 $\rightarrow$ 3-4)-O-3-C-metil-6-desoxi- β -D-manopiranosil-(1 $\rightarrow$ 3)-O-4-O-metil-6-desoxi- β -D-galactopiranosil-(1 $\rightarrow$ 4)-2,6-di-O-metil- β -D-manopiranosido de O-(1R)-4-O-(2,4-dihidroxi-6-metilbenzoil)-2,3-O-metileno-D-xilopiranosilideno-(1 $\rightarrow$ 3-4)- α -L-lixopiranosilo

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impaires des listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.